Scholarlink

<p>The lack of immunity and microbial infection that leads to sepsis is a potentially fatal condition of respiratory infection. Despite this, the development of current therapies and treatments for sepsis is hindered. Antibiotic-containing polymers linked together might enable sustainable drug release mechanisms. The CIF@CS nanocomposite (NCs) is stable in dispersion and generates ultra-fine particles that remain stable in aqueous conditions. The encapsulation of ciprofloxacin antibiotic in a chitosan biopolymer increased the crosslinking of targeted molecules. The antibacterial properties of Chitosan and ciprofloxacin will reveal a synergistic impact on ROS-mediated bacterial inhibition. Antibacterial activity studies demonstrated that the CIF@CS system eliminated human pathogenic microorganisms at minimal concentrations. Anti-fungal properties investigations reveal good growth suppression against <i>Candida albicans fungi</i>&#xa0;and <i>Aspergillus fumigatus</i>. Lastly, the L929 cytocompatibility study shows that the constructed CIF@CS NCs are safe for biological applications. The study results emphasize the development of intelligent drug delivery for sepsis control.</p> Graphical Abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Fabrication of chitosan-coated ciprofloxacin drug nanocomposite for combating antibacterial and respiratory infection leading to sepsis

  • 期刊论文

  • 发表日期：

    2025年1月10日

查看全文
  • Haoguang Li,
  • Zizhan Su

摘要

The lack of immunity and microbial infection that leads to sepsis is a potentially fatal condition of respiratory infection. Despite this, the development of current therapies and treatments for sepsis is hindered. Antibiotic-containing polymers linked together might enable sustainable drug release mechanisms. The CIF@CS nanocomposite (NCs) is stable in dispersion and generates ultra-fine particles that remain stable in aqueous conditions. The encapsulation of ciprofloxacin antibiotic in a chitosan biopolymer increased the crosslinking of targeted molecules. The antibacterial properties of Chitosan and ciprofloxacin will reveal a synergistic impact on ROS-mediated bacterial inhibition. Antibacterial activity studies demonstrated that the CIF@CS system eliminated human pathogenic microorganisms at minimal concentrations. Anti-fungal properties investigations reveal good growth suppression against Candida albicans fungi and Aspergillus fumigatus. Lastly, the L929 cytocompatibility study shows that the constructed CIF@CS NCs are safe for biological applications. The study results emphasize the development of intelligent drug delivery for sepsis control.

Graphical Abstract